Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register

Abstract

In this population-based setting, progression rates appear comparable to that reported from clinical trials, with similar dismal patient outcome. Improved adherence to CML guidelines may minimise the risk of disease progression.